ClinicalTrials.gg
CompletedNCT04506645Updated Dec 20, 2022

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

A Phase 1 interventional study of REGN5381 and Placebo in Healthy, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of REGN5381 in healthy normotensive and otherwise healthy hypertensive adults.

The secondary objectives of the study are:

  • To evaluate the effect of single IV doses of REGN5381 on blood pressure (BP) and heart rate (HR) in healthy normotensive and otherwise healthy hypertensive adults
  • To evaluate the effect of single IV doses of REGN5381 on cardiac stroke volume (SV)
  • To evaluate the pharmacokinetics (PK) of single IV doses of REGN5381
  • To evaluate the immunogenicity of single IV doses of REGN5381
02

Conditions studied

  • Healthy

Keywords

  • Normal Blood Pressure (BP)
  • Mildly Elevated BP
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Normal or mildly elevated blood pressure as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. History of cardiovascular disease as defined in the protocol
  2. Protocol-defined risk factors for cardiovascular disease
  3. History of unexplained syncope, autonomic dysfunction, or neurologic disease.

NOTE: Additional Inclusion / Exclusion criteria apply

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    REGN5381

    Single dose REGN5381 administered via IV infusion

    Drug: REGN5381

  • Other
    Placebo

    Placebo matching single dose REGN 5381 administered via IV infusion

    Other: Placebo

Interventions

  • Single dose REGN5381 administered via IV infusion

  • OtherPlacebo

    Placebo matching single dose REGN 5381 administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: Up to Day 78

Secondary outcomes

  1. Change from baseline in Systolic Blood Pressure (SBP)

    Time frame: Up to Day 78

  2. Change from baseline in Diastolic Blood Pressure (DBP)

    Time frame: Up to Day 78

  3. Change from baseline in Mean Arterial Pressure (MAP)

    Time frame: Baseline to Day 4

  4. Change from baseline in Pulse Pressure (PP)

    Time frame: Baseline to Day 4

  5. Change from baseline in Heart Rate (HR)

    Time frame: Up to Day 78

  6. Change from baseline in Stroke Volume (SV)

    Time frame: Baseline to Day 4

  7. Maximum change from baseline in SBP across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  8. Maximum change from baseline in DBP across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  9. Maximum change from baseline in MAP across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  10. Maximum change from baseline in PP across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  11. Maximum change from baseline in HR across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  12. Maximum change from baseline in SV across the first 24 hours postdose

    Time frame: Baseline to Day 2 (24-hours post dose)

  13. Change from baseline in the 24-hour mean SBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

    Baseline 24-hour mean SBP is measured from 0 to 24 hours pre-dose

    Time frame: Baseline to 24 hours postdose, 24 hours to 48 hours postdose, 48 hours to 72 hours postdose

  14. Change from baseline in the 24-hour mean DBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

    Baseline 24-hour mean DBP is measured from 0 to 24 hours pre-dose

    Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

  15. Change from baseline in the 24-hour mean MAP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

    Baseline 24-hour mean MAP is measured from 0 to 24 hours pre-dose

    Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

  16. Change from baseline in the 24-hour mean PP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

    Baseline 24-hour mean PP is measured from 0 to 24 hours pre-dose

    Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

  17. Change from baseline in the 24-hour mean HR measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

    Baseline 24-hour mean HR is measured from 0 to 24 hours pre-dose

    Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

  18. Concentrations of REGN5381 over time

    Time frame: Up to Day 78

  19. Number of subjects who develop anti-drug antibodies (ADA) and titers

    Time frame: Up to Day 78

  20. Percentage of subjects who develop anti-drug antibodies (ADA) and titers

    Time frame: Up to Day 78

07

Study locations

2 sites
  • Ghent University
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Leuven Gasthuisberg Campus
    Leuven, B-3000, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2022, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Aug 10, 2020
StartActual
Sep 1, 2020
Primary completionActual
Dec 14, 2022
CompletionActual
Dec 14, 2022
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04506645
Responsible party
Sponsor
First posted
Aug 10, 2020
Start date
Sep 1, 2020
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Last update
Dec 20, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vixticibart

Start the discussion